Giardiasis

Etiology

The protozoan parasite G duodenalis (formerly Giardia lamblia and Giardia intestinalis) is the causative agent of giardiasis. The lifecycle of G duodenalis includes 2 stages—a replicative trophozoite stage and an infectious cyst stage. In the environment, G duodenalis persists as a small, hardy cyst. Following ingestion, each cyst releases 2 bilaterally symmetrical, pear-shaped, binucleate trophozoites, each equipped with 4 pairs of flagella. The trophozoites reproduce asexually, with some undergoing encystation and being excreted in feces.[4] Cysts can remain viable in the environment for weeks to months under favorable conditions, and infection may result from ingestion of as few as 10 cysts.[4][5] Human infection occurs through ingestion of contaminated cysts in food, water, or the fecal-oral route, either through direct person-to-person transmission or zoonotic exposure.[6]

Although the taxonomy of the Giardia genus has varied historically, 6 species are currently recognized, with only G dudenalis known to infect humans. G dudenalis is further divided into 8 genetic assemblages (A-H), but only assemblages A and B have been identified in humans. The remaining assemblages appear to be host-specific to other mammals.[7][8]

Epidemiology

Giardiasis is a common enteric protozoal infection globally, with prevalence estimates ranging from 1% to 8% among asymptomatic children in high-income countries and 4% to 30% in low-income countries.[9] In the Nordic region, for example, prevalence was reported at 2.9% in asymptomatic individuals and 5.8% in symptomatic cases.[10]

Socioeconomic disparities are also evident at the local level, with 1 socially deprived Italian community showing a prevalence as high as 42.9%. Studies further suggest that infection rates are slightly higher in immunocompromised hosts.[9]

Giardiasis is the most commonly diagnosed intestinal parasite in the United States. Between 2011 and 2012, incidence rates were estimated at 6.5 and 5.8 cases per 100,000 population, respectively. Rates were higher in the Northwest and Northeast compared to the Midwest, South, and Southwest, though this may reflect differences in surveillance rather than true variation. A bimodal age distribution is observed, with a peak incidence in children aged 1 to 9 and a secondary peak in adults aged 45 to 49. Overall, rates are higher in males, and cases most commonly occur in late summer, particularly in July and August.[11]

Giardia cysts are transmitted through the fecal-oral route, primarily by ingesting contaminated water. Sources include untreated freshwater, inadequately treated tap water, and recreational exposure in both treated and untreated swimming areas.[6] Person-to-person transmission is well-documented, particularly through direct contact with fecal matter. Recognized risk factors include diarrhea, childcare settings, and diapered children.[2] Sexual transmission of G duodenalis has also been reported, with male-male sexual contact identified as a risk factor.[2][12] Transmission through contaminated food and zoonotic spread from animals to humans has likewise been documented.

Pathophysiology

Intermediate hosts are unnecessary in the Giardia lifecycle. Cysts excreted in stool are immediately infectious. Upon ingestion, exposure to the gastric acidity triggers excystation in the small intestine, releasing trophozoites. These trophozoites replicate asexually via repeated mitotic division. When exposed to the bile conditions of the small intestine, some trophozoites encyst, and the newly formed cysts are excreted in stool, thereby continuing the transmission cycle.[8]

The mechanisms underlying the symptoms of giardiasis are not fully understood. Trophozoites possess a large adhesive disc on their ventral surface, which enables them to attach to the mucosa of the proximal small bowel.[4] This adherence can cause structural and functional abnormalities, including villous atrophy, increased crypt depth, and shortening of microvilli. Disruption of epithelial tight junctions may impair epithelial integrity and survival. Secondary effects include deficiencies in brush border enzymes, such as disaccharidases, contributing to malabsorption, altered gastrointestinal transit, and perturbations of the host microbiome.[13]

Histopathology

A biopsy is not required to diagnose suspected giardiasis. However, if performed during the evaluation of chronic diarrhea, histopathology may show either normal findings or mild to subtotal villous atrophy. Following treatment and clinical improvement, a repeat biopsy typically demonstrates restoration of standard villous architecture.[13]

History and Physical

Up to 15% of individuals infected with G duodenalis are asymptomatic. Among symptomatic patients, the most common presentations are diarrhea (>90%), flatulence (75%), abdominal pain (78%), and bloating. Vomiting and fever are less common symptoms, reported in 40% and 27% of cases, respectively. Bloody diarrhea is uncommon (<12%) and should raise concern for alternative or concurrent pathology.[1][14] Acute symptoms typically appear within 1 to 2 weeks of exposure and may resolve spontaneously within 1 to 4 weeks.[1]

Acquired lactase deficiency, resulting from intestinal epithelial damage, develops in up to 40% of patients. This condition manifests as worsening gastrointestinal symptoms following dairy ingestion and may persist for weeks despite the parasite being cleared.[15]

If left untreated in the acute setting, some patients may progress to chronic giardiasis. Compared to acute infections, chronic cases (lasting more than 6 weeks) more often present with intermittent, waxing, and waning diarrhea.[14] In both acute and chronic giardiasis, dehydration and weight loss are common, mainly due to diarrhea and malabsorption.

Extraintestinal manifestations of giardiasis are uncommon, but occur more frequently in chronic cases. Reported findings include rash (particularly urticaria), dysuria, arthritis, and ocular symptoms.[14] These symptoms may be a result of the host's immune system being activated.

Physical examination findings are typically unremarkable in giardiasis. Signs of dehydration may be present, while fever is uncommon but possible. Abdominal tenderness might be elicited upon palpation, and borborygmi may be appreciated on auscultation. Extraintestinal manifestations such as conjunctival redness or discharge, rash, or arthritis may also occur.[14]

Evaluation

The Centers for Disease Control and Prevention recommends that giardiasis be included in the differential diagnosis for patients with persistent diarrhea lasting longer than 3 days.[11] Healthcare professionals should also consider giardiasis in patients presenting with diarrhea and exposure to relevant risk factors, including international travel, contact with diapered children, male-male sexual contact, or exposure to natural bodies of water.[2] Chronic giardiasis should remain a consideration in cases of prolonged diarrhea, malabsorption, vitamin deficiencies, or failure to thrive, even in the absence of known exposure to G duodenalis.

Traditionally, giardiasis was diagnosed by identifying trophozoites or cysts in stool samples using microscopy. Although microscopy remains in use, more sensitive and convenient methods are now widely available, including molecular assays (such as polymerase chain reaction (PCR)-based tests), enzyme-linked immunosorbent assays, and rapid immunochromatographic cartridge assays.

Test sensitivity is improved by collecting 3 stool samples over several days.[16] Antigen-based testing demonstrates sensitivities of around 92%, whereas PCR-based methods may reach up to 99%.[17][18] Despite the availability of these newer techniques, stool microscopy remains valuable for detecting other intestinal parasites that may be part of the differential diagnosis.

Routine laboratory tests, such as complete blood count and electrolyte levels, are typically unremarkable in giardiasis. Eosinophilia is uncommon and only rarely observed.

Treatment / Management

Treatment is generally not required for asymptomatic patients with G duodenalis infection but may be considered to reduce transmission to vulnerable populations. Treatment may be considered in cases such as healthcare or childcare workers, food handlers, contacts of immunocompromised or pregnant individuals, and if the asymptomatic patient themselves is immunocompromised.

Management of symptomatic giardiasis consists of supportive care and antimicrobial therapy. The Infectious Diseases Society of America recommends supportive measures, including oral rehydration for mild dehydration and intravenous rehydration for more severe cases.[19] Electrolyte replacement may also be necessary, depending on the severity of the diarrhea and the amount of fluid loss. Infants and pregnant patients are particularly vulnerable to dehydration, making timely and adequate rehydration especially critical in these groups.(A1)

As most cases of giardiasis are self-limited, antibiotic treatment is not always required.[20] When treatment is indicated, several agents are effective:(B3)

• Metronidazole is widely used, although not approved by the Food and Drug Administration (FDA) for the treatment of giardiasis. Metronidazole is inexpensive, but it is associated with gastrointestinal adverse effects and lower efficacy compared to tinidazole.[3][19]
  • 250 mg orally 3 times daily for 5 to 7 days in adults
  • 5 mg/kg 3 times daily for 5 to 7 days in children
(A1)

• Tinidazole is FDA-approved for the treatment of giardiasis and is considered the most effective agent for this condition.[19] This agent demonstrates higher parasitological and clinical cure rates than metronidazole and is better tolerated.[3][19][21]
  • Single 2 g dose in adults 
  • 50 mg/kg (up to 2 g) orally once in children older than 3
(A1)

• Nitazoxanide is also FDA-approved for giardiasis. This agent has a comparable efficacy to metronidazole and tinidazole.[3][19]
  • 500 mg orally twice daily for 3 days in adults
  • 200 mg twice daily for 3 days in children aged 4 to 11
  • 100mg twice daily for 3 days in children aged 1 to 3
(A1)

Alternative agents include albendazole, mebendazole, and paromomycin. Albendazole, in particular, has demonstrated similar cure rates to metronidazole with fewer adverse effects. Single-day dosing regimens with metronidazole have also been explored.[3](A1)

Treatment of pregnant patients poses additional challenges. Tinidazole is contraindicated in early pregnancy, and data regarding metronidazole safety are mixed. In such cases, paromomycin is generally recommended when antimicrobial therapy is necessary.[22][23]  (B3)

Management of patients with persistent symptoms after treatment for giardiasis requires a systematic approach. Treatment failure is increasingly recognized, often due to resistance to nitroimidazole, with up to 50% of cases refractory to first-line therapy in some settings.[24][25][26][27] For confirmed refractory cases, combination therapy with a 5-nitroimidazole (eg, metronidazole) and albendazole, or quinacrine monotherapy, is an effective second-line option.[25][28](A1)

Repeat stool testing is indicated if symptoms persist after treatment, as recommended by the Centers for Disease Control and Prevention and the Infectious Diseases Society of America.[29] Routine follow-up testing is not recommended unless results indicate management issues, such as suspected treatment failure or multidrug resistance. 

Distinguishing reinfection from true treatment failure is essential. Reinfection is common in endemic areas or with ongoing exposure, whereas true failure may reflect drug resistance or inadequate therapy.[19][25] A detailed exposure history is crucial for identifying ongoing risks, including travel, water sources, and household contacts.[30] Hygiene and environmental factors play a major role in recurrent infection.(A1)

Differential Diagnosis

When evaluating patients with suspected giardiasis, it is important to consider other conditions that may present with similar gastrointestinal symptoms. The differential diagnosis varies with symptom duration and includes:

• Traveler's diarrhea
• Cryptosporidiosis
• Cyclospora or Cystoisospora infection
• Viral gastroenteritis
• Irritable bowel syndrome
• Inflammatory bowel disease
• Tropical sprue

Prognosis

The prognosis for patients with giardiasis is generally favorable, with most symptomatic cases resolving spontaneously within 2 to 4 weeks. Most infections are asymptomatic, and some patients may experience persistent or recurrent symptoms. Chronic or recurrent giardiasis is more likely to occur in children, immunocompromised individuals, and those with ongoing exposure to contaminated water or environments with poor hygiene.[20][31][32]

Chronic infection or postinfectious sequelae, such as irritable bowel syndrome, malabsorption, and growth or cognitive impairment in children, can occur.[33][34] The risk of chronic symptoms is increased in young children, especially those younger than 2, and in individuals with repeated or untreated infections.[31] Postinfectious complications, including irritable bowel syndrome and lactose intolerance, may persist for weeks to months after parasitic clearance.[19] Most patients fully recover, but a minority may develop chronic gastrointestinal or extraintestinal complications. 

Complications

Common complications of giardiasis include weight loss, dehydration, and a transient acquired lactase deficiency. In chronic cases, more persistent complications may develop, such as malabsorption, vitamin deficiencies, anemia, and growth failure or failure to thrive in children.[1][33][34]

Extraintestinal complications, including ophthalmic symptoms, reactive arthritis, chronic fatigue syndrome, and dermatologic changes (eg, urticaria), are less common but occur more frequently in chronic giardiasis.[14][34][35] These complications are believed to result from immune-mediated dysregulation, chronic inflammation, and malabsorption, rather than direct invasion of tissues by the parasite.